SMO and acute myeloid leukemia: Most prior drug development has focused on developing inhibitors of the G protein-coupled receptor (GPCR) and HH signal transducer SMO, and SMO inhibitors are used in the clinic for the treatment of patients with basal cell carcinoma, medulloblastoma, and acute myeloid leukemia (Wu et al., 2017).